title: Epidemiology and treatment patterns of epithelial ovarian cancer.
abstract: While ovarian cancer (OC) is relatively rare, it remains one of the most fatal cancers. Lack of robust screening methods for eOC lead to detection of most cases at advanced stages, and most patients relapse following initial treatment. Areas covered: This review summarizes epidemiology and treatment patterns of epithelial ovarian cancer (eOC). MEDLINE, EMBASE, conference proceedings, and the Cochrane Library were searched using key terms and Medical Subject Headings for ovarian cancer, treatment patterns, and epidemiology to identify articles published from 2005-2015. Expert commentary: To improve early detection, future studies should focus on the identification of biomarkers that can detect asymptomatic disease. Following diagnosis and eventual relapse, response to first-line platinum appears to guide physicians' choice of subsequent therapies, but we do not understand what patients ultimately receive or its relationship to categories of response to first-line platinum. Improved understanding of later-line treatment patterns, by initial response to platinum, could correlate with overall outcomes among relapsed patients and promote development of more effective treatment guidelines. Novel treatment approaches, such as immunotherapies, would fulfill a need for an effective strategy against advanced stages of OC that results in fewer toxic side effects.
authors.affiliation: a Truven Health Analytics , an IBM Company , Ann Arbor , MI , USA.
authors.forename: Philip
authors.initials: P
authors.lastname: Jessmon
authors.affiliation: b Truven Health Analytics , an IBM Company , Cambridge , MA , USA.
authors.forename: Talia
authors.initials: T
authors.lastname: Boulanger
authors.affiliation: c Merck Sharpe & Dohme Corporation, a subsidiary of Merck & Co., Inc ., Kenilworth , NJ , USA.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhou
authors.affiliation: c Merck Sharpe & Dohme Corporation, a subsidiary of Merck & Co., Inc ., Kenilworth , NJ , USA.
authors.forename: Pallavi
authors.initials: P
authors.lastname: Patwardhan
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D000077216:Carcinoma, Ovarian Epithelial; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008403:Mass Screening / Q000379:methods*; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D017671:Platinum Compounds / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D017671:Platinum Compounds
keywords: Epidemiology; epithelial ovarian cancer; incidence; ovarian cancer; patterns; prevalence; treatment